News

According to a new study, higher omega-3 levels significantly reduce the risk of heart failure and heart failure fatalities.

A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showed the greatest improvements in those with the most weight loss at 52 weeks.

A new subanalysis presented by Dr. Mikhail Kosiborod shows benefits of semaglutide in patients with atrial fibrillation.

Consumer Reports On Health talked to Dr. Bethany Austin and Austin Workman about strategies to improve quality of life for those living with heart failure.

Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.

During Heart Month, we are talking about the risks of undiagnosed heart failure and treatment options for those with heart failure.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Through the Havertys' generosity, the Center has been able to create a national model of care called the Cardiometabolic Center Alliance.

When Shannon Clarke, a 48-year-old, retired police officer, received a heart from Saint Luke’s Mid America Heart Institute, he had no idea just how transformational it would be. 

Trial device helps Seabrun “Candy” Hunter’s worn heart valve pump at a steady beat.